Fig. 6

Quininib (1) and ace-quininib-HCl (3) significantly reduce viability of OMM2.5 and SUIT2-007 cells. (A) A dose-dependent, significant decrease in OMM2.5 cell metabolic activity was observed following 96 h treatment with quininib (1) or ace-quininib-HCl (3) in comparison to 0.5 % DMSO treatment. One-way ANOVA with Dunnett's Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001. (N = 3–5). (B) IC50 value of ace-quininib-HCl (3) in OMM2.5 cells following a 96 h treatment, as determined by metabolic activity assays. (C) Images of clones captured by GelCount™ system (Oxford Optronix) after 8 days of culture following treatment with DMSO control or 10 μM quininib (1) or 10 μM ace-quininib-HCl (3) for 96 h. Clones were stained with 0.5 % crystal violet before counting. 2000 cells were seeded and treated in duplicate in 6-well plates for each individual experiment and individual experiments were conducted three times. (D) Graphs show the percentage survival fraction of clones at 96 h post treatment with 10 μM quininib (1) or 10 μM ace-quininib-HCl (3) (left) and with 20 μM quininib (1) or 20 μM ace-quininib-HCl (3) (right). Statistical analysis was performed by ANOVA with Dunnett's post hoc multiple comparison test. Error bars are mean + SEM, ∗∗p < 0.01; ∗∗∗∗p < 0.0001. N = 3. (E) A dose-dependent, significant decrease in SUIT2-007 cell metabolic activity was observed following 96 h treatment with ace-quininib-HCl (3) in comparison to 0.125 % DMSO treatment. One-way ANOVA with Dunnett's Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, ∗∗∗∗p < 0.0001 (N = 3). (F) IC50 value of ace-quininib-HCl (3) in SUIT2-007 cells following a 96 h treatment, as determined by metabolic activity assays.